Related Experiment Videos
[The use of cefotaxime against infections (author's transl)]
Abstract:
Cefotaxime was administered as sole treatment (49 cases) or after failure of another previous antibiotic (17 cases) to 66 patients suffering from infectious diseases. The 78 infections thus treated included urinary tract infections (35), septicaemia or endocarditis (25), respiratory tract infections (7), osteitis (5), meningitis (4), biliary infection (1), and skin infection (1). The pathogens identified were more often enterobacteria: Serratia: 23, E. coli: 15, Klebsiella: 7, Proteus: 7, Enterobacter: 1, Providentia: 1, Pseudomonas: 5, Staphylococcus: 7, Pneumococcus: 4, Streptococcus: 2, Branhamella: 1. Cefotaxime was given either intravenously (2/3 of cases) or intramuscularly, at an average daily dose of 3.75 g (mean: 1.5-8 g). It was administered alone to 49 patients suffering from septicaemia and urinary tract infections caused by E. coli, Klebsiella and especially Serratia, and it was combined in 17 cases, particularly in meningitis and bone infections. The overall results of cefotaxime given in serious diseases were especially favourable in debilitated patients (88% therapeutic success). The local tolerance was good and side effects were not observed in any patient. Cefotaxime seems to be an active antibiotic, indicated in many severe septicemic or not septicemic infections, more particularly in diseases with multiresistant Gram negative pathogens.
Insights
Cefotaxime demonstrated high efficacy in treating severe bacterial infections, including those caused by multi-resistant Gram-negative pathogens. This antibiotic showed favorable outcomes, particularly in debilitated patients, with good local tolerance and no observed side effects.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pharmacology
Context:
- 66 patients with serious infectious diseases were treated with cefotaxime.
- Infections included urinary tract, septicaemia, endocarditis, respiratory, osteitis, and meningitis.
- Common pathogens were enterobacteria (Serratia, E. coli, Klebsiella) and Staphylococcus.
Purpose:
- To evaluate the efficacy and safety of cefotaxime in treating severe infections.
- To assess cefotaxime's effectiveness as a sole agent or in combination therapy.
- To determine cefotaxime's utility against multi-drug resistant Gram-negative bacteria.
Summary:
- Cefotaxime was administered to 66 patients, either as monotherapy (49 cases) or after prior antibiotic failure (17 cases).
- The treatment covered 78 infections, with a high prevalence of enterobacteria and Staphylococcus.
- An average daily dose of 3.75 g was given intravenously or intramuscularly, with favorable results in 88% of debilitated patients.
Impact:
- Cefotaxime proved effective in treating severe septicemic and non-septicemic infections.
- The antibiotic is particularly indicated for infections caused by multi-resistant Gram-negative pathogens.
- Good local tolerance and absence of side effects were noted, suggesting a favorable safety profile.